Ogivri Alternatives Compared
Ogivri | Palbociclib | Kisqali |
|
---|
Ogivri (trastuzumab) | Palbociclib | Kisqali (ribociclib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Breast Cancer, Breast Cancer - Metastatic, Breast Cancer - Adjuvant, Esophageal Carcinoma, Gastric Cancer. Ogivri may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer - Metastatic, Liposarcoma, Breast Cancer, Breast Cancer - Male. palbociclib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Kisqali may also be used for purposes not listed in this medication guide. |
||||||||||||||||
More about Ogivri (trastuzumab) | More about Palbociclib | More about Kisqali (ribociclib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Palbociclib has an average rating of 6.9 out of 10 from a total of 98 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 29% reported a negative effect. |
Kisqali has an average rating of 8.5 out of 10 from a total of 25 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 4% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: Ogivri side effects in more detail. |
See also: palbociclib side effects in more detail. |
See also: Kisqali side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
N/A |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Ogivri prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Kisqali prices |
||||||||||||||||
Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Other trastuzumab brands include: Herceptin, Hercessi, Herzuma, Kanjinti, Ontruzant, Trazimera | Ibrance |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
924 hours |
29 hours |
54.7 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 178 drugs are known to interact with Ogivri:
|
A total of 458 drugs are known to interact with palbociclib:
|
A total of 710 drugs are known to interact with Kisqali:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
December 01, 2017 |
N/A |
March 13, 2017 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.